ITI-007 (Lumateperone Tosylate) for Schizophrenia

Schizophrenia Clinical Trial

Official title:

ITI-007 (Lumateperone Tosylate) for Schizophrenia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03817528
• Other study ID #: 7716
• Status: Terminated
• Phase: Phase 2
• Start date: March 1, 2019
• Est. completion date: September 23, 2020

Study information

• Verified date: November 2021
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to offer open label ITI-007 treatment to patients who poorly respond or poorly tolerate approved medications.

Description:

Patients will be started on ITI-007 and current medication will be slowly discontinued within the first 7 days of starting ITI-007, with some flexibility allowed if clinically indicated. No patients will be left unmedicated because of this study.

Patients will be seen weekly for the first 4 weeks, biweekly for the second month and then monthly for six months. Patients will be monitored by clinical and safety rating scales, and will be required to show improvement after 3 months to remain in this study. Patients not improving at this time will be assessed for the risks/benefits of continuing.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: September 23, 2020
• Est. primary completion date: September 23, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnosis of schizophrenia or schizoaffective disorder

• Has capacity to provide informed consent

• Medically stable for study participation

• Judged clinically not to be at significant suicide or violence risk

• Inadequate response or tolerability to previously antipsychotic therapy, as defined by at least one of the following: prior clozapine failure, a PANSS>80 despite at least six weeks of a current antipsychotic therapy, a Clinical Global Impressions scale-Improvement (CGI-I) of 4 after at least two six week trials of antipsychotics (retrospective assessment) or failure to tolerate an adequate dose of at least antipsychotics (as defined by the Physicians Desk Reference)

Exclusion Criteria:

• Substance abuse within last 90 days

• ECG abnormality that is clinically significant

• Pregnancy, lactation, or lack of use of effective birth control

• Presence or positive history of significant unstable medical or neurological illness (including any history of seizure disorder, hepatitis, renal insufficiency or mental retardation), history of HIV

• Clinically significant abnormal laboratory tests, positive for hepatitis B or C or liver function tests (LFTs) > 2x Upper Limit of Normal, use of strong CYP3A4 inhibitors or inducers

• History or presence of concomitant major psychiatric illness.

• Use of other antipsychotic medications at baseline.

• Use of another investigational medication in the previous 4 weeks

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• ITI-007
ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events

Locations

Country	Name	City	State
United States	New York State Psychiatric Institute	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
New York State Psychiatric Institute	Intra-Cellular Therapies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Schizophrenia Symptoms	schizophrenia symptoms will be measures using the Positive and Negative Symptom Scale (PANSS) Total PANSS score (range: 30-210). Individual items scored from 1(absent) to 7 (extremely severe). Total PANSS score is sum of the 30 individual items with lowest score (30) indicating all symptoms absent and the maximum score (210) indicating all symptoms rated as extremely severe.	Change from baseline in Total PANSS score after 6 month treatment